Literature DB >> 30857975

Incidence, Technical Safety, and Feasibility of Coronary Angiography and Intervention Following Self-expanding Transcatheter Aortic Valve Replacement.

Akihito Tanaka1, Richard J Jabbour1, Luca Testa2, Mauro Agnifili2, Federica Ettori3, Claudia Fiorina3, Marianna Adamo3, Giuseppe Bruschi4, Cristina Giannini5, Anna Sonia Petronio5, Marco Barbanti6, Corrado Tamburino6, Francesco De Felice7, Bernhard Reimers8, Arnaldo Poli9, Antonio Colombo1, Azeem Latib10.   

Abstract

BACKGROUND: Transcatheter aortic valve replacement (TAVR) is a well-established treatment option for severe aortic stenosis (AS). AS and coronary artery disease frequently coincide, and therefore some patients may require coronary angiography (CAG) and/or intervention (PCI) post-TAVR. Due to valve stent design, most self-expanding prostheses always cover the coronary ostium, and therefore may hinder future access. The objective of this research was to evaluate the incidence, safety and feasibility of CAG/PCI in patients with prior self-expanding TAVR valves.
METHODS: Among 2170 patients (age 82 ± 6 years, 43% male) who underwent TAVR with Corevalve or Evolut prostheses, as part of the Italian CoreValve ClinicalService® framework (data from 13 Italian centers), the occurrence of CAG/PCI following TAVR and periprocedural characteristics were examined.
RESULTS: During median follow-up of 379 days, 41 patients (1.9%) required CAG and/or PCI (total 46; 16 CAG, 14 PCI, 16 both PCI/CAG). 56.5% of the procedures were performed under emergency/urgency settings. Left system coronary angiography was successfully performed in most cases (28/32, 87.5%), while right coronary angiography was successful only in 50.0% (16/32). PCI procedures (20 for left system, 3 for right system, 4 for graft) were successfully performed in 93.3% (28/30) of the procedures. No CAG/PCI procedure-related complications including prosthesis dislodgment or coronary ostium dissection occurred.
CONCLUSIONS: CAG and PCI procedures following CoreValve TAVR is safe and mostly feasible, although the success rate of selective right coronary angiography was relatively low when compared to the left system. Further investigations are required to explore this issue.
Copyright © 2019. Published by Elsevier Inc.

Entities:  

Keywords:  CAG; PCI; Self-expanding valve; TAVI; TAVR

Mesh:

Year:  2019        PMID: 30857975     DOI: 10.1016/j.carrev.2019.01.026

Source DB:  PubMed          Journal:  Cardiovasc Revasc Med        ISSN: 1878-0938


  4 in total

1.  Technical Characteristics and Feasibility of Coronary Angiography and Percutaneous Coronary Interventions Performed after Transcatheter Aortic Valve Replacement with Self-Expanding Valves.

Authors:  Chuan-Tsai Tsai; Hsiao-Huang Chang; Hsin-Bang Leu; Kan Ling; I-Ming Chen; Po-Lin Chen; Su-Man Lin; Ying-Hwa Chen
Journal:  Acta Cardiol Sin       Date:  2022-01       Impact factor: 2.672

2.  Coronary Access and Percutaneous Coronary Intervention Up to 3 Years After Transcatheter Aortic Valve Implantation With a Balloon-Expandable Valve.

Authors:  Giuseppe Tarantini; Luca Nai Fovino; Pascal Le Prince; Olivier Darremont; Marina Urena; Antonio L Bartorelli; Flavien Vincent; Tomas Hovorka; Yasmina Alcalá Navarro; Nicolas Dumonteil; Patrick Ohlmann; Olaf Wendler
Journal:  Circ Cardiovasc Interv       Date:  2020-06-25       Impact factor: 6.546

3.  Case Report: Emergency High-Risk Percutaneous Coronary Intervention Following Transcatheter Aortic Valve Implantation in Bicuspid Anatomy.

Authors:  Ahmed El-Medany; Gemina Doolub; Amardeep Dastidar; Nikhil Joshi; Thomas Johnson; Stephen Dorman
Journal:  Front Cardiovasc Med       Date:  2021-01-20

4.  Complexity assessment and technical aspect of coronary angiogram and percutaneous coronary intervention following transcatheter aortic valve implantation.

Authors:  Nils Perrin; Amir Fassa; Antoine Baroz; Caroline Frangos; Stephane Mock; Angela Frei; Murat Cimci; Sophie Degrauwe; Marco Roffi; Juan Fernando Iglesias; Stephane Noble
Journal:  Cardiol J       Date:  2020-05-21       Impact factor: 2.737

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.